Eurasian Hematology-Oncology Group

http://www.ehog.net/

 

MDS and MPN
15:05

7th Eurasian Hematology Oncology Summit

2020 Updates on MDS: Is Deferasirox Beneficial for EFS? Can We Achieve Transfusion Independence With Luspatercept? Does IV-DEC Mono Prolong the Duration of Response?

FEATURING Guillermo Garcia-Manero
  • 168 views
  • December 11, 2020
18:36

7th Eurasian Hematology Oncology Summit

2020 Update on High-Risk MDS: Does Aza Improve OS/ORR? How to Minimize Toxicity? Is Cytarabine Still the SoC? Are Novel Agents Promising?

FEATURING Moshe Mittelman
  • 64 views
  • December 11, 2020
11:32

7th Eurasian Hematology Oncology Summit

2020 Updates on MDS: Role of Prognostic Models, Cytogenetics, IPSS, Genomics, Comorbidites, Response to HMA

FEATURING Guillermo Garcia-Manero
  • 96 views
  • December 11, 2020
26:20

7th Eurasian Hematology Oncology Summit

2020 Update on MPNs: What Is the Risk Adapted Management in PV? Is Ropeginterferon Alfa-2b Effective in Inducing CHR? Can We Achieve Both HCT Control and Spleen Response With Ruxolitinib?

FEATURING Tariq Mughal
  • 117 views
  • December 10, 2020